Pepcid Related Published Studies
Well-designed clinical trials related to Pepcid (Famotidine)
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. [2009.07.11]
Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH. [2009.03]
Can famotidine and omeprazole be combined on a once-daily basis? [2007.06]
Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers. [2007.02]
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. [2006.11]
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. [2006.10]
Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. [2006.09.01]
Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective? [2006.04]
Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. [2006.01]
Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study. [2005.12]
Effect of preoperative short course famotidine on TILs and survival in breast cancer. [2005.10]
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. [2005.07.01]
Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine. [2005.07]
A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. [2005.06]
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. [2005.06]
New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. [2005.06]
Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. [2005.06]
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. [2005.06]
Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. [2005.06]
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. [2005.06]
Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. [2005.06]
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. [2005.02.15]
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. [2005.02]
Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial. [2005]
Pharmacokinetics of famotidine in infants. [2005]
The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. [2004.08]
The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. [2004.01]
Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. [2003.06]
Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. [2003.05.01]
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. [2003.02]
Randomized comparative study of omeprazole and famotidine in reflux esophagitis. [2002.09]
Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity. [2002.07]
Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. [2002.04]
Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. [2002]
Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine. [2001.10]
Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. [2001.08]
Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. [2001.05]
Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design. [2001]
A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine. [2000.11]
Famotidine in the treatment of acute urticaria. [2000.05]
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. [1999.08]
Impact of food intake on the antisecretory effect of low-dose ranitidine and famotidine. [1999.03]
Pharmacokinetics of famotidine in patients with cystic fibrosis. [1998.11]
Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy? [1998.10]
Low-dose famotidine and effervescent cimetidine in healthy subjects: a placebo-controlled overnight pH study. [1998.05]
Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone. [1998.05]
Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. [1998.04]
The action of 10 mg famotidine versus 200 mg cimetidine: onset and magnitude of antisecretory action within the first 2 hours after administration. [1998.03]
A randomized clinical trial comparing the efficacy of ranitidine and famotidine on intragastric acidity in critically ill pediatric patients. [1998.03]
Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. [1997.12]
Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori--a randomized, double-blind comparison of a three times daily and twice daily regimen. [1997.11]
Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease. [1997.06]
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. [1997.06]
Prevention of heartburn relapse by low-dose famotidine: a test meal model for duration of symptom control. [1997.02]
On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets. [1997.01]
Prophylaxis against acid aspiration in regional anesthesia for elective cesarean section: a comparison between oral single-dose ranitidine, famotidine and omeprazole assessed with fiberoptic gastric aspiration. [1996.12]
Low-dose famotidine and ranitidine as single post-prandial doses: a three-period placebo-controlled comparative trial. [1996.10]
Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. [1996.07]
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. [1996.05.30]
Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. [1996.05.08]
Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. [1996.04]
Comparison of roxatidine and famotidine on nocturnal gastric juice secretion. [1996.01]
Premedication with famotidine augments core hypothermia during general anesthesia. [1995.12]
Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis. [1995.11]
Safety and cost of rapid i.v. injection of famotidine in critically ill patients. [1995.09.01]
Ranitidine suspension or famotidine resoriblette and gastric fluid volume and pH. [1995.09]
Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal. [1995.08]
Efficacy and Tolerability of Famotidine in Preventing Heartburn and Related Symptoms of Upper Gastrointestinal Discomfort. [1995.05]
Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. [1995.05]
Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study. [1995.04]
Novel oral medication delivery system for famotidine. [1995.04]
Effects of intravenous famotidine on gastric acid secretion in patients undergoing cardiac surgery. [1995.04]
Maintenance of gastric pH above 6 with intravenous famotidine in patients with a bleeding duodenal ulcer. [1995.04]
Comparative evaluation of the hemodynamic effects of oral cimetidine, ranitidine, and famotidine as determined by echocardiography. [1995.03]
Randomized comparison of gastric pH control with intermittent and continuous intravenous infusion of famotidine in ICU patients. [1995.02]
Hemodynamic effects of intravenous famotidine in patients undergoing cardiac surgery. [1995.01]
Efficacy of famotidine in patients with acute gastric mucosal injury after continuous infusion of cisplatin plus vindesine. [1995]
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study. [1995]
Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial. [1995]
Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. [1995]
Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study. [1995]
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. [1995]
Effects of oral ranitidine, famotidine and omeprazole on gastric volume and pH at induction and recovery from general anaesthesia. [1994.10]
Acid aspiration prophylaxis in elective biliary surgery. A comparison of omeprazole and famotidine using manually aided gastric aspiration. [1994.10]
Effect of H2-receptor antagonists cimetidine and famotidine on interdigestive gastric motor activity and lower esophageal sphincter pressure in progressive systemic sclerosis. [1994.07]
Assessment of 24-hour gastric pH measurements in trauma patients receiving intravenous famotidine by intermittent bolus versus continuous infusion administration. [1994.07]
Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) does not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer. [1994.05]
Effect of a 28-day therapy with famotidine on blood levels of alcohol and gastrin and intragastric pH in healthy human subjects. [1994.05]
[The effect of ranitidine and famotidine on the intragastric pH profile of healthy subjects. Randomized cross-over trial with ranitidine effervescent tablets (300 mg) versus famotidine film tablets (40 mg) ] [1994.05]
Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. [1994.04]
Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. [1994.04]
Comparison of the effects of single morning and single bedtime doses of famotidine on intragastric acidity in patients with gastric ulcer. [1994.02]
Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. [1994.02]
Famotidine increases plasma alcohol concentration in healthy subjects. [1994.02]
The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. [1993.12]
Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. [1993.12]
Dose-response study of oral famotidine for reduction of gastric acidity and volume in outpatients and inpatients. [1993.12]
A controlled comparison of continuous ranitidine and intermittent famotidine infusions on gastric pH. [1993.12]
Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. [1993.11.15]
Gastric acid suppression is greater during intravenous ranitidine infusion versus bolus injections of famotidine. [1993.10]
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. [1993.08]
|
